Jacobs Engineering Group Inc. (NYSE:JEC) received an engineering, procurement, construction management and validation (EPCmV) services contract for the new Ferring Pharmaceuticals research and development (R&D) headquarters, which will be located in Copenhagen, Denmark. Jacobs was selected for this project phase following the successful completion of the conceptual study and basic engineering design. As Ferring Pharmaceuticals' principal biopharmaceutical product development center, this new facility will feature collaborative work spaces and serve as an inspirational, global Research & Development unit for identifying and developing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopedics. When constructed, the facility will include six stories above grade, two basement levels, and a site area of approximately 124,000 square feet (11,500 square meters). Jacobs is working alongside Foster + Partners, an architecture consultancy firm, to develop the iconic vision for the new R&D center. "Our clients turn to Jacobs because we provide the biopharmaceutical labs and corporate building expertise they need, as well as end-to-end solutions for delivering their facility to completion," said Jacobs Buildings & Infrastructure and Industrial President Bob Pragada. Jacobs is one of the world's largest and most diverse providers of full-spectrum technical, professional and construction services for industrial, commercial and government organizations globally. The company employs over 54,000 people and operates in more than 25 countries around the world. For more information, visit www.jacobs.com. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our Form 10-K for the year ended September 30, 2016, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.